Φορτώνει......
Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease
BACKGROUND: Ustekinumab and briakinumab are monoclonal antibodies that target the standard p40 subunit of cytokines interleukin‐12 and interleukin‐23 (IL‐12/23p40), which are involved in the pathogenesis of Crohn's disease (CD). A significant proportion of people with Crohn's disease fail...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Cochrane Database Syst Rev |
|---|---|
| Κύριοι συγγραφείς: | , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
John Wiley & Sons, Ltd
2019
|
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6906134/ https://ncbi.nlm.nih.gov/pubmed/31828765 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD012804.pub2 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|